Predictions of CYP-Mediated Drug-Drug Interactions Using Cryopreserved Human Hepatocytes: Comparison of Plasma and Protein-Free Media Incubation Conditions

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Prediction of CYP2D6 Drug Interactions from In Vitro Data: Evidence for Substrate-Dependent Inhibition

  2012cited by this paper
• Prediction of CYP3A-Mediated Drug-Drug Interactions Using Human Hepatocytes Suspended in Human Plasma

  2011influential reference
• Prediction of Human Drug-Drug Interactions from Time-Dependent Inactivation of CYP3A4 in Primary Hepatocytes Using a Population-Based Simulator

  2009cited by this paper
• Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction

  2009cited by this paper
• The effect of different sulfonamides on phenytoin metabolism in man.

  2009cited by this paper
• A Combined Model for Predicting CYP3A4 Clinical Net Drug-Drug Interaction Based on CYP3A4 Inhibition, Inactivation, and Induction Determined in Vitro

  2008cited by this paper
• Prediction of Pharmacokinetic Drug-Drug Interactions Using Human Hepatocyte Suspension in Plasma and Cytochrome P450 Phenotypic Data. II. In Vitro-in Vivo Correlation with Ketoconazole

  2008cited by this paper
• Potential role of intestinal first-pass metabolism in the prediction of drug–drug interactions

  2008cited by this paper
• Prediction of Pharmacokinetic Drug-Drug Interactions Using Human Hepatocyte Suspension in Plasma and Cytochrome P450 Phenotypic Data. III. In Vitro-in Vivo Correlation with Fluconazole

  2008cited by this paper
• Prediction of metabolic clearance using fresh human hepatocytes: Comparison with cryopreserved hepatocytes and hepatic microsomes for five benzodiazepines

  2008cited by this paper
• Effect of Aprepitant on the Pharmacokinetics of Intravenous Midazolam

  2007cited by this paper
• Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation.

  2007cited by this paper
• Comparison of different approaches to predict metabolic drug–drug interactions

  2007cited by this paper
• A Novel Model for the Prediction of Drug-Drug Interactions in Humans Based on in Vitro Cytochrome P450 Phenotypic Data

  2007cited by this paper
• Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam.

  2006cited by this paper
• Comparison of midazolam and simvastatin as cytochrome P450 3A probes

  2006cited by this paper
• Avoiding physicochemical artefacts in early ADME-Tox experiments.

  2006cited by this paper
• Prediction of hepatic clearance using cryopreserved human hepatocytes: a comparison of serum and serum‐free incubations

  2006cited by this paper
• The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions

  2006influential reference
• Drug adsorption to plastic containers and retention of drugs in cultured cells under in vitro conditions.

  2006cited by this paper
• Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant.

  2005influential reference
• EVALUATION OF TIME-DEPENDENT INACTIVATION OF CYP3A IN CRYOPRESERVED HUMAN HEPATOCYTES

  2005influential reference
• Mechanism-Based Inactivation of CYP3A by HIV Protease Inhibitors

  2005influential reference
• Sensitivity of Intravenous and Oral Alfentanil and Pupillary Miosis as Minimally Invasive and Noninvasive Probes for Hepatic and First‐Pass CYP3A Activity

  2005cited by this paper
• PREDICTION OF CYP2C9-MEDIATED DRUG-DRUG INTERACTIONS: A COMPARISON USING DATA FROM RECOMBINANT ENZYMES AND HUMAN HEPATOCYTES

  2005cited by this paper
• Modulation of Metoprolol Pharmacokinetics and Hemodynamics by Diphenhydramine Coadministration during Exercise Testing in Healthy Premenopausal Women

  2005cited by this paper
• Change in enantioselectivity in bufuralol 1''-hydroxylation by the substitution of phenylalanine-120 by alanine in cytochrome P450 2D6.

  2005cited by this paper
• Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity.

  2004cited by this paper
• 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions.

  2004cited by this paper
• Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide

  2004cited by this paper
• Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine

  2004cited by this paper
• Effect of the novel anxiolytic drug deramciclane on cytochrome P450 2D6 activity as measured by desipramine pharmacokinetics

  2004cited by this paper
• An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates.

  2004cited by this paper
• Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites.

  2004cited by this paper
• Database analyses for the prediction of in vivo drug-drug interactions from in vitro data.

  2004cited by this paper
• Influence of albumin binding on the substrate transport mediated by human hepatocyte transporters OATP2 and OATP8

  2003cited by this paper
• Stereoselectivity in the oxidation of bufuralol, a chiral substrate, by human cytochrome P450s.

  2003cited by this paper
• Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers

  2003cited by this paper
• Pharmacokinetic and Pharmacodynamic Interactions of Oral Midazolam with Ketoconazole, Fluoxetine, Fluvoxamine, and Nefazodone

  2003cited by this paper
• Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe

  2003cited by this paper
• Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 10th Edition

  2002cited by this paper
• Effect of albumin on phenytoin and tolbutamide metabolism in human liver microsomes: an impact more than protein binding.

  2002cited by this paper
• Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride

  2001cited by this paper
• Effect of fluconazole on plasma fluvastatin and pravastatin concentrations

  2000cited by this paper
• Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity

  2000cited by this paper
• Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers

  2000influential reference
• Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole

  1999cited by this paper
• The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6.

  1999cited by this paper
• Concurrent Administration of the Erythromycin Breath Test (EBT) and Oral Midazolam as In Vivo Probes for CYP3A Activity

  1999cited by this paper
• Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential.

  1999cited by this paper
• Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174

  1998cited by this paper
• Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver.

  1998cited by this paper
• Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers.

  1997cited by this paper
• Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers

  1997cited by this paper
• The effect of sertraline on the pharmacokinetics of desipramine and imipramine

  1997cited by this paper
• Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices.

  1997cited by this paper
• The Effect of the Systemic Antimycotics, Itraconazole and Fluconazole, on the Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Midazolam

  1996cited by this paper
• Metoprolol metabolism via cytochrome P4502D6 in ethnic populations.

  1996cited by this paper
• Paroxetine shifts imipramine metabolism.

  1996cited by this paper
• PREDICTION OF IN VIVO DRUG DISPOSITION FROM IN VITRO DATA BASED ON PHYSIOLOGICAL PHARMACOKINETICS

  1996cited by this paper
• Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies.

  1996cited by this paper
• Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.

  1995influential reference
• Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine.

  1994cited by this paper
• Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine

  1993cited by this paper
• Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction

  1992cited by this paper
• Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man.

  1992cited by this paper
• Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects

  1992cited by this paper
• Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers.

  1991cited by this paper
• Effect of fluconazole on the disposition of phenytoin

  1991cited by this paper
• Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man.

  1991cited by this paper
• Drug Interactions with Fluconazole

  1990cited by this paper
• Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers

  1990cited by this paper
• Genetically determined steady-state interaction between encainide and quinidine in patients with arrhythmias.

  1990cited by this paper
• Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism.

  1989cited by this paper
• Palmitate uptake by cultured hepatocytes: albumin binding and stagnant layer phenomena.

  1989cited by this paper
• Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect.

  1989cited by this paper
• Clearance approaches in pharmacology.

  1987influential reference
• Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency.

  1987cited by this paper
• Goodman & Gilman's The Pharmacological Basis of Therapeutics

  1985cited by this paper
• Hepatic uptake of albumin-bound substances: albumin receptor concept.

  1983cited by this paper
• Effect of albumin binding on the hepatic transport of rose bengal: surface-mediated dissociation of limited capacity.

  1982cited by this paper
• Receptor for albumin on the liver cell surface may mediate uptake of fatty acids and other albumin-bound substances.

  1981cited by this paper
• Blood-tissue exchange in liver and heart: the influence of heterogeneity of capillary transit times.

  1977cited by this paper
• Blood-tissue exchange in liver and heart: the influence of heterogeneity of capillary transit times.

  1977cited by this paper
• Kinetics of bilirubin binding to bovine serum albumin and the effects of palmitate.

  1977cited by this paper
• A new method for the measurement of dissociation rates for complexes between small ligands and proteins as applied to the palmitate and bilirubin complexes with serum albumin.

  1974cited by this paper

• Cytotoxicity evaluation using cryopreserved primary human hepatocytes in various culture formats.

  2016cites this paper
• Prediction of fraction metabolized via CYP3A in humans utilizing cryopreserved human hepatocytes from a set of 12 single donors

  2014cites this paper
• Risk assessment of drug–drug interactions using hepatocytes suspended in serum during the drug discovery process

  2014influential citation